Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06228066 · ClinicalTrials.gov registry record · Phase 2
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
A Phase 2 study of Small Cell Carcinoma of the Bladder and High Grade Neuroendocrine Tumors of the Urinary Tract, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT06228066 is a Phase 2 study of Small Cell Carcinoma of the Bladder and High Grade Neuroendocrine Tumors of the Urinary Tract that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06228066, a Phase 2 study of Small Cell Carcinoma of the Bladder and High Grade Neuroendocrine Tumors of the Urinary Tract, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed with SCCB or HGNET is about 1 year. Lurbinectedin and avelumab are drugs that are approved to treat other cancers. Researchers want to see if these drugs can help people with SCCB or HGNET. Objective: To test lurbinectedin with or without avelumab in people with SCCB or HGNET. Eligibility: Adults aged 18 years and older with SCBB or HGNET that returned and spread after treatment. Design: Participants will be screened. They will have a physical exam. They will have blood tests and imaging scans. They may need to have a new biopsy: A small needle will be used to collect a tissue sample from the tumor. Both study drugs are given through a tube attached to a needle inserted into a vein. If participants have already received a drug like avelumab they will receive only lurbinectedin. If patients have not been previously treated with a drug like avelumab they will receive both lurbinectedin and avelumab. All participants will receive their treatment once every 3 weeks for up to 10 years. They will also receive other drugs to relieve adverse effects. Biopsies, blood tests, and imaging scans will be repeated during some study visits. Participants may also have urine tests and tests of their heart function. Participants may remain in the study as long as the treatment is helping them. If they stop treatment, they will have safety visits 14, 30, and 90 days after their last dose. Additional follow-up visits will continue 5 to 10 years.
Conditions Studied
Interventions
- DRUG Avelumab
- DRUG Lurbinectedin
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-06-13 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06228066
The ClinicalTrials.gov registry entry for NCT06228066 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Small Cell Carcinoma of the Bladder appearing as the primary indexed condition, and to 2 interventions - of which Avelumab is the first listed.
NCT06228066 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06228066 about?
NCT06228066 is a clinical study titled "Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)". Background: Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed with SCCB or HGNET is about 1 year. Lurbinectedin and avelumab are drugs that are approved to treat o...
What is the current status of trial NCT06228066?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2024-06-13. Estimated completion is 2028-09-01.
What conditions does trial NCT06228066 study?
This clinical trial studies the following conditions: Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract.
What interventions are being tested in trial NCT06228066?
The interventions under investigation include: Avelumab (DRUG), Lurbinectedin (DRUG).
Who is sponsoring clinical trial NCT06228066?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06228066 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Carcinoma of the Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Small Cell Carcinoma of the Bladder
All registered trials for this condition
High Grade Neuroendocrine Tumors of the Urinary Tract
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.